Greenhill Can 'Certainly Replenish' M&A Backlog: CEO

The transcript discusses Greenhill's acquisition of Allegance's generic drugs unit, highlighting the $50 million fee. CEO Scott Bach explains the company's diverse business model, emphasizing that no single client represents a significant portion of revenue. The discussion covers the impact of big deals and the importance of a diverse transaction pipeline. Recent transactions, including Emerson's acquisition and TEGNA's spinoff of cars.com, are highlighted, showcasing strategic business decisions and industry trends.

What was the recent acquisition mentioned in the text?

How much in fees will the company receive according to the text?

What does the CEO, Scott Bach, suggest about the nature of their business?

What is the significance of the top ten transactions mentioned?

What strategy is TEGNA employing with its recent spinoff?